CompletedPhase 2NCT01335932

Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

Studying Acute lung injury

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fred Hutchinson Cancer Center
Principal Investigator
Michael Boeckh, MD, M.D
Fred Hutchinson Cancer Center
Intervention
IV Ganciclovir(drug)
Enrollment
160 enrolled
Eligibility
18 years · All sexes
Timeline
20112016

Study locations (14)

Collaborators

National Heart, Lung, and Blood Institute (NHLBI) · Genentech, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01335932 on ClinicalTrials.gov

Other trials for Acute lung injury

Additional recruiting or active studies for the same condition.

See all trials for Acute lung injury

← Back to all trials